Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medtech Matters

Medtech Matters artwork

Three Systems of Risk

Sep 7, 202144 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we look at the three systems of risk as they relate to the U.S. regulatory system. While many are familiar with the device classification system, they may not be as familiar with the other two systems or their purpose. Whether or not all three systems are actually needed is also explored. Specifically, the following questions are addressed: First, can you explain how we handle risk in medtech manufacturing in the U.S.? What is the medical device classification system and why do we have it? What is the Significant Risks vs. Non-Significant Risk system? What about software? What is the Software classification system? How are the three systems of risk related? Do we need three separate systems to handle risk? What are the most important items medical device manufacturers need to keep in mind with regard to risk? Listen to this episode and see what you think of the three systems of risk. If you’d like to share thoughts, ask questions, or have a suggestion for a future topic for us to cover, please reach out to me at sfenske@rodmanmedia.com and we’ll see if we want to address your ideas/inquiries/suggestions in a future episode. Send us Fan Mail For more medtech news and information, visit https://www.mpomag.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. An Early Look at FDA’s Guidance Focus for 2027, Part 2

    Nov 2, 20261 hr 2 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re continuing the conversation of guidance documents that are expected to gain the attention of the agency...

    Credit the people on this episode

  2. An Early Look at FDA’s Guidance Focus for 2027, Part 1

    Nov 2, 202647 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we review the list of guidances FDA expects to begin to focus on in 2027. The list really represents the...

    Credit the people on this episode

  3. A Preview of MDUFA VI: Changes and Highlights, Part 2

    Sep 11, 202650 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re into part 2 of the discussion in an early look at the next Medical Device User Fee Act, MDUFA VI, which...

    Credit the people on this episode

  4. A Preview of MDUFA VI: Changes and Highlights, Part 1

    Sep 11, 202648 minAudio

    In this Medtech Matters podcast episode of Mike on Medtech with Mike Drues, president of Vascular Sciences, we’re taking an early look at the next version of the Medical Device User Fee Act, MDUFA VI, which would go...

    Credit the people on this episode

  5. The Value in Partnering for Sterility Testing

    Sep 9, 202626 minAudio

    In this Medtech Matters podcast episode, sponsored by Nelson Labs, two representatives from the company offer their expertise and insights on sterility testing. Amina Rahmoune, Laboratory Operations Manager - Sterility...

    Credit the people on this episode